scholarly journals Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis

2002 ◽  
Vol 16 (6) ◽  
pp. 1149-1156 ◽  
Author(s):  
M. Vallve ◽  
M. Vergara ◽  
J. P. Gisbert ◽  
X. Calvet
2008 ◽  
Vol 134 (4) ◽  
pp. A-337 ◽  
Author(s):  
Albert Villoria ◽  
Xavier Calvet ◽  
Pilar Garcia ◽  
Javier P. Gisbert ◽  
Valentí Puig Diví

2007 ◽  
Vol 147 (8) ◽  
pp. 553 ◽  
Author(s):  
Lorenzo Fuccio ◽  
Maria Eugenia Minardi ◽  
Rocco Maurizio Zagari ◽  
Diego Grilli ◽  
Nicola Magrini ◽  
...  

2010 ◽  
Vol 138 (5) ◽  
pp. S-340 ◽  
Author(s):  
Haydee B. Flores ◽  
Angela Salvana ◽  
Ena Lyn R. Ang ◽  
Norberto I. Estanislao ◽  
Marie Ellaine Velasquez ◽  
...  

2021 ◽  
Vol 96 (1) ◽  
pp. 13-21
Author(s):  
Yong Hwan Kwon

Helicobacter pylori (H. pylori) is the main cause of most gastroduodenal diseases. Triple therapy including two antibiotics, amoxicillin and clarithromycin, and a proton pump inhibitor given for a week has been recommended as the treatment of choice since the revision of the Korean H. pylori Clinical Practice Guidelines in 2013. However, antimicrobial resistance significantly decreased the cure rate of H. pylori eradication to 63.9%. Thus, the new H. pylori treatment regimen would be needed to increase the eradication rate in Korea. Recently, the update of clinical practice guideline for treatment of H. pylori was developed by conducting a meta-analysis. In this review, the recommended H. pylori eradication regimen in current 2020 guideline will be discussed.


Sign in / Sign up

Export Citation Format

Share Document